Referencia número: HY-15557

AZ20

10 Cited Publications

Revisión del cliente

Based on 10 publication(s) in Google Scholar

AZ20 is a potent and selective inhibitor of ATR with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.40%
No. CAS: 1233339-22-4
Fòrmula: C₂₁H₂₄N₄O₃S
Peso molecular:412.51

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AZ20 Chemical Structure

No. CAS: 1233339-22-4

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (10)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

AZ20 is a potent and selective inhibitor of ATR with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

IC₅₀ & Target^[1]

ATR

5 nM (IC₅₀)

mTOR

38 nM (IC₅₀)

PI3Kα

13000 nM (IC₅₀)

Ver todos los productos específicos de isoformas ATM/ATR :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.46 μM Compound: 4; AZ20	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
A549	IC₅₀	0.333 μM Compound: AZ20	Synergistic antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of oxaliplatin by MTT assay Synergistic antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of oxaliplatin by MTT assay	[PMID: 36462444]
A549	IC₅₀	0.481 μM Compound: AZ20	Synergistic antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of cisplatin by MTT assay Synergistic antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of cisplatin by MTT assay	[PMID: 36462444]
A549	IC₅₀	0.495 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay	[PMID: 36462444]
A549	IC₅₀	0.7 μM Compound: AZ20	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 35191694]
A549	IC₅₀	0.734 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
BT-474	IC₅₀	>30 μM Compound: 6, AZ20	Inhibition of PI3Kalpha-mediated AKT phosphorylation at threonine 308 in human BT474 cells Inhibition of PI3Kalpha-mediated AKT phosphorylation at threonine 308 in human BT474 cells	[PMID: 23394205]
CAPAN-1	IC₅₀	7.05 μM Compound: 4; AZ20	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
DLD-1	IC₅₀	3.47 μM Compound: 4; AZ20	Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
Granta-519	IC₅₀	0.5 μM Compound: 4; AZ20	Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
HCT-116	IC₅₀	0.092 μM Compound: AZ20	Synergistic antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of oxaliplatin by MTT assay Synergistic antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of oxaliplatin by MTT assay	[PMID: 36462444]
HCT-116	IC₅₀	0.137 μM Compound: AZ20	Synergistic antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of cisplatin by MTT assay Synergistic antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of cisplatin by MTT assay	[PMID: 36462444]
HCT-116	IC₅₀	0.151 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay	[PMID: 36462444]
HCT-116	IC₅₀	0.26 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
HCT-116	IC₅₀	1.47 μM Compound: 4; AZ20	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
HeLa	IC₅₀	0.005 μM Compound: 6, AZ20	Inhibition of ATR in human HeLa cell nuclear extracts using glutathione S-transferase-p53N66 and ATP as substrate incubated for 10 mins prior to ATP addition measured after 1 hr by ELISA Inhibition of ATR in human HeLa cell nuclear extracts using glutathione S-transferase-p53N66 and ATP as substrate incubated for 10 mins prior to ATP addition measured after 1 hr by ELISA	[PMID: 23394205]
HT-29	GI₅₀	0.97 μM Compound: 1; AZ20	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 30346772]
HT-29	IC₅₀	>30 μM Compound: 6, AZ20	Inhibition of ATM-mediated autophosphorylation at serine 1981 in human HT29 cells Inhibition of ATM-mediated autophosphorylation at serine 1981 in human HT29 cells	[PMID: 23394205]
HT-29	IC₅₀	>30 μM Compound: 6, AZ20	Inhibition of DNA-PK-mediated autophosphorylation at serine 2056 in human HT29 cells Inhibition of DNA-PK-mediated autophosphorylation at serine 2056 in human HT29 cells	[PMID: 23394205]
HT-29	IC₅₀	0.05 μM Compound: 6, AZ20	Inhibition of ATR-mediated CHK1 phosphorylation at serine 345 in human HT29 cells after 1 hr in presence of 4-nitroquinoline 1-oxide Inhibition of ATR-mediated CHK1 phosphorylation at serine 345 in human HT29 cells after 1 hr in presence of 4-nitroquinoline 1-oxide	[PMID: 23394205]
HT-29	IC₅₀	0.072 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell viability incubated for 3 days in presence of AZD-1390 by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	0.644 μM Compound: AZ20	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	2.94 μM Compound: 4; AZ20	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
LoVo	GI₅₀	0.2 μM Compound: 1; AZ20	Cytotoxicity against human LoVo cells after 72 hrs by MTS assay Cytotoxicity against human LoVo cells after 72 hrs by MTS assay	[PMID: 30346772]
LoVo	GI₅₀	0.2 μM Compound: 6, AZ20	Growth inhibition of human LoVo cells after 72 hrs by MTS assay Growth inhibition of human LoVo cells after 72 hrs by MTS assay	[PMID: 23394205]
LoVo	IC₅₀	0.231 μM Compound: AZ20	Antiproliferative activity against ATM-deficient human LoVo cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-deficient human LoVo cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
LoVo	IC₅₀	0.85 μM Compound: 4; AZ20	Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
MCF7	IC₅₀	1.221 μM Compound: AZ20	Synergistic antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days in presence of olaparib by MTT assay Synergistic antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days in presence of olaparib by MTT assay	[PMID: 36462444]
MCF7	IC₅₀	2.31 μM Compound: AZ20	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
MDA-MB-231	IC₅₀	0.254 μM Compound: AZ20	Synergistic antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days in presence of olaparib by MTT assay Synergistic antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days in presence of olaparib by MTT assay	[PMID: 36462444]
MDA-MB-231	IC₅₀	2.97 μM Compound: AZ20	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
MDA-MB-468	IC₅₀	2.4 μM Compound: 6, AZ20	Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells	[PMID: 23394205]
NCI-H446	IC₅₀	3.9 μM Compound: 4; AZ20	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
OCI-Ly10	IC₅₀	1.03 μM Compound: 4; AZ20	Antiproliferative activity against human OCI-Ly10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human OCI-Ly10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
OVCAR-3	IC₅₀	0.563 μM Compound: AZ20	Antiproliferative activity against ATM-deficient human OVCAR-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-deficient human OVCAR-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
PC-3	IC₅₀	8.43 μM Compound: 4; AZ20	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
SUD4	IC₅₀	2.38 μM Compound: 4; AZ20	Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
SW-620	IC₅₀	0.727 μM Compound: AZ20	Antiproliferative activity against ATM-deficient human SW620 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-deficient human SW620 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]

In Vitro

AZ20 inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC₅₀ of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC₅₀ of 50 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AZ20 (25, 50 mg/kg, p.o.) has high permeability combined with good stability to rat hepatocytes and, despite the lack of progress in achieving markedly higher solubility, has respectable bioavailability in a low dose rat PK study. AZ20 (25, 50 mg/kg, p.o.) leads to significant tumor growth inhibition in female nude mice bearing LoVo tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 1233339-22-4
Appearance Solid
Peso molecular 412.51
Fòrmula C₂₁H₂₄N₄O₃S
Color White to off-white
SMILES

O=S(C1(C2=CC(N3[C@H](C)COCC3)=NC(C4=CC=CC5=C4C=CN5)=N2)CC1)(C)=O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All WB

Sort by:

Journal Impact Factor

Nat Commun

E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells. [Abstract]

2025 Jul 21;16(1):6677. PMID: 40691182
Nat Commun

Active DNA damage response signaling initiates and maintains meiotic sex chromosome inactivation. [Abstract]

2022 Nov 28;13(1):7212. PMID: 36443288
Nat Commun

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. [Abstract]

2019 Jul 2;10(1):2910. PMID: 31266951
Mol Cell

Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination. [Abstract]

2021 Mar 4;81(5):1084-1099.e6. PMID: 33450211
Cell Death Dis

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. [Abstract]

2017 Aug 10;8(8):e2982. PMID: 28796244

AZ20 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2017 Aug 10;8(8):e2982. [Abstract]

Tumor pieces from M130116 PDXs treated with the vehicle or the RVX2135/AZ20 combination treatment are subjected to western blot analysis.
Cell Syst

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. [Abstract]

2020 Jan 22;10(1):66-81.e11. PMID: 31812693
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Life Sci Alliance

SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness. [Abstract]

2020 Feb 18;3(4):e201900427. PMID: 32071280
Life Sci Alliance

Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. [Abstract]

2020 Jun 22;3(8):e202000671. PMID: 32571801
bioRxiv

2026 Jun 2.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (242.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4242 mL

12.1209 mL

24.2418 mL

5 mM

0.4848 mL

2.4242 mL

4.8484 mL

10 mM

0.2424 mL

1.2121 mL

2.4242 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

Compound dose ranges are created by diluting in 100% DMSO and then further into assay medium (EMEM, 10% FCS, 1% glutamine) using a Labcyte Echo acoustic dispensing instrument. Cells are plated in 384-well Costar plates at 9×10⁴ cells per mL in 40 μL of EMEM, 10% FCS, 1% glutamine and grown for 24 h. Following addition of compound the cells are incubated for 60 min. A final concentration of 3 μM 4NQO (prepared in 100% DMSO) is then added using the Labcyte Echo, and the cells are incubated for a further 60 min. The cells are fixed by adding 40 μL of 3.7% v/v formaldehyde solution for 20 min. After removal of fix, cells are washed with PBS and permeabilized in 40 μL of PBS containing 0.1% Triton X-100. The cells are then washed, and 15 μL primary antibody solution (pChk1 Ser345) is added. The plates are incubated at 4°C overnight. The primary antibody is then washed off, and 20 μL of secondary antibody solution and 1 μM Hoechst 33258 added for 90 min at room temperature. The plates are washed and left in 40 μL of PBS. Plates are then read on an ArrayScan VTI instrument to determine staining intensities, and dose responses are obtained and used to determine the IC₅₀ values for the compounds.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Female Swiss nu/nu mice are housed in negative pressure isolators. LoVo tumor xenografts are established in 8- to 12-week-old mice by injecting 1×10⁷ tumor cells subcutaneously (100 μL in serum free medium) on the left dorsal flank. Animals are randomized into treatment groups when tumors become palpable. AZ20 is prepared in 10% DMSO/40% propylene glycol/50% water and administered orally. Tumors are measured up to three times per week with calipers. Tumor volumes are calculated and the data plotted using the geometric mean for each group versus time.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Foote KM, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4242 mL	12.1209 mL	24.2418 mL	60.6046 mL
	5 mM	0.4848 mL	2.4242 mL	4.8484 mL	12.1209 mL
	10 mM	0.2424 mL	1.2121 mL	2.4242 mL	6.0605 mL
	15 mM	0.1616 mL	0.8081 mL	1.6161 mL	4.0403 mL
	20 mM	0.1212 mL	0.6060 mL	1.2121 mL	3.0302 mL
	25 mM	0.0970 mL	0.4848 mL	0.9697 mL	2.4242 mL
	30 mM	0.0808 mL	0.4040 mL	0.8081 mL	2.0202 mL
	40 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5151 mL
	50 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2121 mL
	60 mM	0.0404 mL	0.2020 mL	0.4040 mL	1.0101 mL
	80 mM	0.0303 mL	0.1515 mL	0.3030 mL	0.7576 mL
	100 mM	0.0242 mL	0.1212 mL	0.2424 mL	0.6060 mL

Keywords

AZ20

10 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

AZ20

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AZ20

Ver todos los productos específicos de isoformas ATM/ATR

Actividad biológica

Chemical Information

Publications (10)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

AZ20

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AZ20

Ver todos los productos específicos de isoformas ATM/ATR

Actividad biológica

Chemical Information

Publications (10)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

AZ20 Related Classifications

HY-15557 Related Classifications